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South Africa has a high incidence of tuberculosis (TB) and is ranked among the top 30 countries with 
high incidence of the disease according to the Global Tuberculosis Report released by the World Health 
Organization in 2019. There is an urgent need to consider ways in which incidence of TB can be 
reduced so that South Africa can meet the WHO End TB Strategy targets. The problem in South Africa 
is compounded by the high prevalence of human immunodeficiency virus infections (HIV). Prevalence 
surveys have shown at least one-third cases with TB can go undetected thus contributing significantly to 
the disease burden by transmitting this infection to others. Contact tracing is one method which can 
control this mode of spread by tracing close contacts of patients actively and testing them. Cluster 
randomized trials have been inconclusive on contact tracing prompting this modeling study.  
    A compartmental mathematical model in continuous time of TB in South Africa was simulated and 
stratified by HIV and age, till 2019. Contact tracing was then simulated in the settings where three 
factors were varied: a) the average infectious duration for an undetected case of TB, b) the proportion of 
incident cases which were found among contacts and c) percentage of contacts with active TB who were 
traced and treated. The reduction in incidence with these interventions was compared to the reduction 
which would be achieved if current trends in TB in South Africa continued without any interventions.  
  The results showed that as the proportion of contacts among incidence TB patients increased, the 
average duration time of being infectious decreased from 3 months to 6 months and as proportion of 
contacts covered in the intervention increased, the intervention was more effective.  
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Tuberculosis (TB) is the leading cause of death globally from a single infectious agent and among the 
top 10 causes of deaths worldwide (1). In 2018, there were an estimated 10 million new cases of 
tuberculosis globally with 1.5 million people dying due to the infection (1). One million (10%) of these 
were human immunodeficiency virus (HIV) positive. Globally, the incidence of TB has remained static 
since the turn of the 21st century with a 2% drop in incidence from 2000 – 2018 (1). The World Health 
Organization (WHO) End TB Strategy aims to reduce deaths due to TB by 95% and to reduce the 
incidence by 90 between 2015 and 2035 (2). As part of this strategy, the interim targets developed for 
2020 are to reduce deaths due to TB by 35% and incidence by 20%, and for 2025 the target reduction in 
deaths is 75% and target reduction in the incidence is 50% (2).  To meet the 2020 targets for End TB, 
the drop in incidence must equal 4-5% per year which may not be possible given current reductions in 
incidence and mortality (1).  
TB in South Africa is still a substantial problem which is further exacerbated by HIV. In 2018, three 
percent of the global burden of new TB cases occurred in South Africa, with an incidence of 520 per 
100,000 people, down from 759 per 100,000 in 2015 (1). 59% of TB cases occurred in people with HIV 
(PWH) (1). South Africa has the highest burden of HIV in the world with a total of 7.7 million PWH 
(3,4). While South Africa is on track to meet the End TB 2020 target of reducing incidence of TB cases 
by 20% from the 2015, the current drop in incidence rate may not guarantee that South Africa meets the 
2035 goals for End TB Strategy i.e. 95% reduction in TB related deaths and a 90% reduction in TB 
incidence (2,3,5). 
Most of the TB diagnosis is based on passive case finding (PCF) and treatment, wherein symptomatic 
patients present to the clinic of their own accord to be tested and if positive are treated. However, the 
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WHO estimates that one-third of the people with TB are not diagnosed and notified to public health 
authorities – an estimated 3.6 million globally in 2017 (4). Nationwide cluster surveys in the Gambia, 
Vietnam and Zimbabwe have demonstrated a high prevalence of sputum-positive tuberculosis among 
asymptomatic cases, underscoring the importance of active case finding (ACF) that does not rely 
entirely on symptoms (6–8). House to house surveys done in Korea, India and South Africa noted that 
the prevalence of TB increased when asymptomatic cases were tested using either sputum or X-ray and 
symptoms or sputum and X-ray, respectively. The Korean study had 5.4% detection rate (5000/92 000 
examined) at health centers as compared with 2.1% (14000/659000) in the household surveys (9). House 
to house testing while inefficient detected three times more cases than healthcare centers. The study in 
India found that performing X-rays in TST positive populations detected TB at the same rate among 
those who underwent X-rays based on symptoms (10). In South Africa, the official notification figure 
for KwaZulu in 1974 was 177/100 000, compared to a prevalence of 804/100 000 estimated from the 
survey. So, there is a pool of undetected TB infected patients who could be contributing to disease 
spread because they are not diagnosed and treated early (11). According to the National Institute for 
Healthcare and Excellence (NICE) guidelines in UK 2016, “Active case finding is looking 
systematically for cases of active tuberculosis and latent infection in groups known, or thought to be, at 
higher risk of tuberculosis, rather than waiting for people to develop symptoms/signs of active disease 
and present themselves for medical attention (passive case finding)” (12).  
However, information on impact of ACF from randomized controlled trials is mixed. Some studies have 
shown an increased rate of diagnosis with ACF while some have not shown the same results.  In Brazil, 
a study that compared door-to-door testing versus education found a higher rate of diagnosis with the 
door to door testing arm (13). The DETECTB trial in Zimbabwe noted a higher diagnosis rate of TB in 
high TB prevalence communities in Harare, Zimbabwe (8).A cluster randomized trial in Vietnam by Fox 
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et al was done which demonstrated a higher incidence rate of tuberculosis among the arm which tested 
household contacts compared to the arm which employed only passive case finding (PCF) (14). The 
ZAMSTAR trial in Zambia and the Western province of South Africa was a 2X2 factorial design cluster 
randomized trial in a high burden area with also a high prevalence of HIV (15). This trial compared 
community interventions and investigation of household contacts to evaluate enhanced case detection 
and a change in the epidemiology of TB in the communities. While differences were not statistically 
significant, the authors did note higher case detection in the contact investigation arm (p=0.06), though 
no difference with community-based enhanced case finding. The reasons for no significant differences 
being detected as postulated by the authors were: a) heterogeneity of TB prevalence among the 
communities being investigated, b) distance between the sample collection and processing laboratories 
leading to denaturation of the samples and c) the fact that the cases who were detected may have already 
been infectious for a long duration and already have transmitted the infection to the others in the 
community. Irrespective of the statistical conclusions, there seems to be some benefit in screening for 
TB in high burden communities from this study which was the first randomized, factorial design which 
looked at not just case detection rates but the overall effect of ACF on the epidemiology of TB within 
communities (15). In a cluster randomized trial in South Africa, Hanrahan et al were unable to document 
a higher rate of detection among contacts with ACF (16). A systematic review on screening for TB 
revealed that there was an increase in the short-term detection of cases in most of these studies, while 
the long-term effects were less certain (17–19). One of the reasons for this could be that the studies were 
usually community-based trials and conducted ACF in the entire community (19).  
Even though the results of cluster randomized trials are mixed, there is still some advantage to testing of 
household contacts. The fact that TB spreads through aerosol production should suggest that close 
exposure to patients with TB will increase the risk of being infected with TB. This has been shown in 
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studies which have looked exclusively at infection rates among contacts (19). Trials which compared 
ACF at the community level versus among contacts also have shown a higher diagnosis rate among 
contacts (14). If the targeted group is at a higher risk of developing TB, then ACF in these special 
populations may help in providing a higher yield of cases than if it was done in the general population. 
Studies have documented results where more than half of prevalent cases were undiscovered with PCF 
(15). There is also evidence that ACF detects cases earlier than PCF (15). Studies have not shown any 
improvement in mortality with ACF, though this is most likely due to survival bias. People are more 
likely to die without anti tuberculosis therapy and before diagnosis. And thus, the mortality rate among 
patients on treatment with anti TB therapy and detected by PCF may underestimate the true mortality 
(19,20). This may lead to an attenuation of the beneficial effect which is provided by ACF. Thus, the 
impact and implementation of ACF depend on four factors: 1) prevalence of the disease, 2) 
epidemiological importance, 3) chances of being detected otherwise and 4) cost (20). In areas of high 
prevalence, the disease burden is high as well as the proportion of undiagnosed TB cases. The 
individual’s risk of getting infected is higher as compared to the general population. ACF may have 
benefit in these settings (20)  Epidemiological importance is more concerned with a certain group or 
individuals and their effect on the community. Those with a higher burden of disease (HIV infected) and 
more likely to infect others should be diagnosed and treated early (20). If the patients have a higher 
chance of getting tested for TB, then ACF may not be very helpful. However, in areas with poor access 
to healthcare, where the chances of early detection are low, then ACF may be useful (20).  Lastly, the 
cost of ACF must be considered with the incremental benefit expected from an increased detection in 
cases (21). Based on these factors i.e. high load of undiagnosed cases and the benefits of ACF in certain 
scenarios, the WHO now recommends ACF among contacts of tuberculosis patients in the context of 
high burden countries (18). To summarize, there is a high burden of active, infectious TB which is 
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undetected, and which needs to be diagnosed. Community level screening programs may not lead to a 
higher diagnosis rate of these people; however, a targeted screening and ACF strategy among contacts 
may lead to earlier and more comprehensive diagnosis with overall survival improvement as well as 
improvement in the transmission dynamics of TB. ACF may aid South Africa in achieving the End TB 
Strategy goals; however, the magnitude of benefit that might accrue to national incidence is unclear.  
The current health system in South Africa is based on a district health system with 52 districts in 9 
provinces and 3500 public healthcare facilities (22). Ninety percent of TB tests and most TB treatment is 
provided in the public health sector (22). Modelling studies in South Africa have also described the 
global trend which is two-thirds of cases being detected with 34% of cases with presumptive TB not 
having any record of testing or treatment (1,(13,23). This missing one-third therefore forms an important 
link in the spread of tuberculosis. Failure to address this 33% may lead to a loss in the gains made over 
the last 3 years. ACF may be one way to address this gap; current TB management in South Africa relies 
primarily on passive case detection: patients presenting with symptoms (16,24). The Kharitode study 
done by Hanrahan et al used an incentive-based strategy and a household-based strategy to test contacts 
of TB patients (16). They were unable to find a substantial increase in TB diagnoses and were unable to 
demonstrate a reduction in incidence of TB. One of the reason postulated was  using Xpert MTB/RIF 
instead of cultures which were used by Fox et al in Vietnam (14). The Kharitode study may have failed 
to show effect because the diagnosis rates of Xpert MTB/RIF test would not have been as sensitive as 
cultures in picking up early stage of the disease among contacts (16). Other reason could have been that 
the communities may have needed more follow up time with the intervention to show a reduction in 
incidence -something that may not have been possible due to logistical factors (16).  As SA has a high 
burden of TB, a high-risk subpopulation with HIV, and many undetected cases, widescale use of ACF 
still has the potential to substantially impact the SA TB epidemic. We therefore conducted a modeling 
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study to assess the impact of ACF on incidence of TB in South Africa and to see if it meets the End TB 
targets of 2030 by allowing the intervention to run for a longer duration of time.  
2.METHODS 
2.1 Model structure  
We created a compartmental, continuous-time model of TB stratified by age and HIV status (Figure 1). 
We represented individuals as being in one of the following TB states: uninfected, latent TB within two 
years of infection (early latent state), latent TB greater than two years after infection (late latent state), 
active TB, and cured. We used age strata of 0-4, 5-14, 15-24, 25-34,45-54, 55-64 and above 65 years 
old, as the prevalence of HIV and TB is different at the extremes of age (24). We used a simplified 
representation of the HIV continuum of care: HIV negative, HIV positive not on ART and HIV positive 
on ART as in a previous study of TB in South Africa (25).  
With respect to TB, individuals who are infected move from the uninfected state to the early latent state; 
the probability of infection depends on individuals’ age and HIV status as well as the prevalence of 
active TB in the total population. If these individuals do not reactivate, they progress to late latent TB 
after two years (26,27) . Individuals in either latent state reactivate at a rate that depends on their age and 
HIV status and is higher for early latent than for late latent TB. Once in the active state, individuals 
contribute to the force of TB infection. They can spontaneously recover, in which case they revert to the 
early latent state, or they can move to the recovered state with treatment, at a rate that depends on 
national treatment rates and the probability of treatment success.  
Individuals in both the late latent and recovered states can be re-infected and revert to the early latent 
state. With respect to HIV, a proportion of children are born HIV-positive due to maternal transmission; 
the remainder of births are HIV-negative. Once individuals have aged into adulthood (15 years old), 
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they are at risk for HIV acquisition. Newly infected individuals start in the HIV-positive not on ART 
state and move to the HIV-positive on ART state, at a rate that is consistent with national estimates of 
ART coverage (3). ART treated individuals may move back to the not on ART state. We did not model 
rates of HIV infection and ART initiation dynamically; instead we set them to historical rates and further 
tuned them to reproduce trends in HIV prevalence and ART coverage over the past two decades. 
We modeled ACF by splitting up the Active cases compartment into two parts: one part was the 
proportion of new cases of TB among non-contacts and the other was the proportion of new cases of TB 
among contacts of TB patients who would be detected earlier by ACF strategy.  
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Figure 1: Model Structure                       Model of TB transmission 
                                          
 
                  Model of HIV: 
                                                                                            




2.2 Model parameters and data sources: 
We replicated the demographic structure of South Africa’s population by using age-specific mortality 
rates starting in 2006, the earliest year for which we could obtain age-stratified mortality rates (24). We 
reproduced the HIV epidemic by adjusting incidence; we used incidence rates and mother-to-child 
transmission going back to 1990 and then calibrated those rates to mimic current prevalence trends in 
South Africa (24). We assumed that all incident HIV in the 0-15 age group represented mother-to-child 
transmission (MTCT) and calibrated this process to WHO estimates (3). The ART discontinuation rates 
were obtained from cohort studies done by Asiimwe et al (28). Mortality rates among the HIV infected 
population were obtained from comparative analysis done on HIV cohorts in sub-Saharan Africa by 
Zaba et al (29). 
The compartmental model reduces to a set of ordinary differential equations. These equations were 
coded in R version 3.6.2 (R Foundation for Statistical Computing, Vienna, Austria) and RStudio 
1.2.5033 and solved using the deSolve package (30) 
Table1: Fixed model parameters:  
 




coverage in South Africa 
(2015) 
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anti-TB therapy in HIV 







































*- This rate is applied only for HIV cases since 2018.  
**- This implies that those with a latent TB infection are protected from reinfection by a factor of 0.28. i.e 28 out of 100 
LTBI cases will be re-infected if re-exposed to TB as opposed to unexposed.  
Table 2: Calibrated model parameters: 
Tuberculosis Infection Rates (Relative Risk in each group) 
 
HIV negative, ≤15 years  
HIV negative,>15 years  






Reactivation Rates of tuberculosis 
Early reactivation: 
HIV negative, ≤15 years  
HIV negative, >15 years 









Successful proportion of 
HIV positive patients not on 
ART treated with anti TB 
therapy 
 
Spontaneous recovery rate 
in HIV negative patients 
 
Rate of ART 
discontinuation 
 
Rate of treatment of TB 






0.058 per person-year 
 
 
0.1411 per person-year  
 
 
1.42 per person-year 
 




0.021 – 0.086 
 
 
0.1406 – 0.1416 
 
 


















Case fatality ratio of TB 
Added Mortality in PWH on 
ART* 
 


















0.004 per person-year 
 






0.0036 – 0.0044 
 









Latent protection factor** 0.28 0.21 – 0.39 (39) 
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HIV negative, ≤15 years  
HIV negative, >15 years 




Mortality Rates in all HIV patients (per 100 person-years)- 
includes on ART and not on ART 
Rate projected from 1994 - 2000 
Rate projected from 2000 - 2018 







Fraction of HIV positive births (per 1000 births)  
Rate projected from1996 - 2017 




Annual Rate of HIV incidence (per 1000 person- years) 
Rate projected from 1990 projected to 2000 
Rate projected from 2000 projected to 2010 
Rate projected from 2010 projected to 2020 






ART initiation rate (per 1000 person -years) 
Rate projected from 2004 - 2010 
Rate projected from 2010 - 2020 
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The transmission and reactivation of TB in our model was governed by parameters described in Table 1 
and Table 2. Most parameters were drawn from a review of the literature (Table 1), but we calibrated 
key parameters to replicate recent trends in the South Africa TB epidemic (Table 2). 
2.3Calibration process: 
We calibrated the HIV incidence, mortality and treatment rates to mimic the current prevalence trends of 
HIV in South Africa, using empiric maximum likelihood estimation, in which we allowed 27 parameters 
to vary to see what combination of parameters yielded the maximum likelihood. Our likelihood function 
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was structured to reproduce the TB and HIV trends in South Africa over the past two decades, and was 
formulated as a product of three components: 
a) TB incidence – we represented the WHO-reported TB incidence from 1970 to 2018. We used the 
least square method to estimate this proportion where the sum of squares between the actual value 
and the simulated model value was minimized using the property of linear regression where in a 
normal distribution the maximum likelihood estimation is equal to the sum of least squares.  
b) HIV prevalence- we represented the WHO-reported HIV prevalence from 1990 to 2018 as a draw 
from independent normal distributions whose mean was the model-estimated incidence and whose 
standard deviation was the half of the confidence interval width divided by 1.96. 
c) Fraction of estimated HIV prevalent patients on ART- we used the WHO reported fraction of 
estimated HIV prevalent patients on ART. The figures are available from 2004 onward. We used the 
least square method to estimate this proportion where the sum of squares between the actual value 
and the simulated value was minimized.  
2.4 Intervention 
We modeled contact tracing as a reduction in the average time during which contacts with active TB 
were infectious. On an average based on current treatment initiation rates in South Africa, on an average 
a person can be infective for 8.5 months before being detected. If contact tracing is carried out then this 
duration should reduce and that is how we represented contact tracing in our model- by reducing the 
average infectious duration from 8.5 months to 3 and 6 months. In exploring the effects of contact 
tracing, we varied three parameters which can impact the effectiveness of contact training: (1) How 
much contact tracing reduces the time during which contacts are infectious, (2) what proportion of all 
incident TB cases are close contacts of other persons with active TB, and (3) what proportion of close 
contacts are screened and treated by the contact training intervention. We evaluated combinations of 
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these three parameters, for an average infectious duration time of 3 months and 6 months. Five values of 
the proportion of incident TB who are contacts (4.5%, 13%, 20% ,30% and 50%), and four values of the 
proportion of contacts reached by screening (25, 50, 75, and 100%). The values of 4.5% and 13% for 
proportion of incident TB cases who are contacts were based on ZAMSTAR and DETECTTB trials 
(8,15). The values of 20%, 30% and 50% were used to assess the impact in localized communities where 
the percentage of TB among contacts was higher. Our primary simulations assumed that the rates of TB 
transmission and reactivation, HIV incidence, and ART initiation remained constant after 2020. We 
tested the impact of these assumptions by performing two sets of sensitivity analyses. The first allowed 
four parameters to continue to change from 2020 to 2030 at the same rate they had changed in the 
previous 10 years. The second sensitivity analysis allowed the four parameters to change, but reach a 
value halfway between the 2020 value and the extrapolated 2030 value and the last allowed the four 
parameters to continue at the same rate as 2020 to 2030.The fours parameters we tested this way were: 
a) reactivation rate, b) ART initiation rate, c) HIV incidence rate and d) force of infection of TB. We ran 
the sensitivity analysis assuming 13% of contacts among incident cases being discovered after an 




Figure 2: Calibration targets Panel A shows the percentage of patients who are on ART as per WHO 
data and that calibrated by our model Panel B shows the prevalence of HIV in South Africa as per data 
and calibrated by our model. Panel C shows the incidence of TB calibrated by our model as compared to 
WHO data. Red lines indicate our model projections while blue lines indicate the trends according to 
WHO data. 
 
Panel A: Percentage of HIV positive patients on ART 
 
Panel B :HIV prevalence in South Africa  
 
 
Panel C:  TB incidence in South Africa 




We first recreated HIV prevalence trends and the fraction of PWH on ART in South Africa. The 
prevalence of HIV was 13.3% (95% CI: 12.3 – 13.3) and the percentage of PWH on ART was 62% 
(95%CI: 57 – 66) according to 2018 WHO estimates (32) After this we recreated the TB incidence 
trends in South Africa and projected it to 2030. 
Our model reproduced calibration targets well (Figure 2). In the absence of any interventions, our model 
projected that the incidence of tuberculosis in South Africa would be 475 per 100,000 persons in 2020 
and 406 per 100,000 people in 2030. This would amount to a reduction of 15.2 % from 2020 if there 
were no interventions, and other trends do not change from the present day. Under the least optimistic 
assumptions about contact tracing (only 4.5% of incident TB cases are contacts, our contact screening 
program reaches 25% of those contacts, averting an average of 2 months of time infectious), we 
projected that the 2030 incidence would be 406 per 100,000, a 15.2% reduction from 2020 (the same as 
not having any intervention at all). This represents negligible relative reduction in incidence from 
contact training. Under the most optimistic assumptions (50% of incident TB cases are contacts, our 
contact screening program reaches 100% of those contacts, averting an average of 5 months of time 
infectious), we projected that the 2030 incidence would be 389 per 100,000 a 19.3% reduction from 
2020, or 3.6% gain compared to no intervention. Table 3 gives the full spectrum of potential reductions 







































Table 3: Projected Reduction in TB Incidence in 2030 after implementing contact tracing* 




B. Contact tracing implemented for 10 years with average infectious time of 6 months 
 
*The percentages in the table above are obtained by subtracting the incidence in 2030 after 
implementing the intervention from the incidence in 2030 without the intervention and scaling it by 
dividing it by incidence in 2030 in the no intervention group and expressing it as a percentage. 
 
3.2 Sensitivity Analysis 
Sensitivity analysis was performed in a population where the proportion of incident TB cases among 
contacts was 13% to assess which parameters would affect the projections the most. When the 
reactivation rates were changed it was noted that the reduction was the same when 2020 values were 
projected over the next 10 years. There was a mild change in the reduction when the reactivation rates 
and TB transmission rates were extrapolated from 2020 values or taken at a midpoint between current 
2020 value and that of an extrapolated value in 2030.  Changing the HIV incidence rate or ART 
% contacts 
treated 
                                     Proportion of incident cases among contacts 
 
 4.5% 10% 13% 20% 30% 50% 
25% 0.4% 0.8% 1% 1.5% 2.3% 3.8% 
50% 0.5% 1.2% 1.5% 2.4% 3.6% 6.2% 
75% 0.7% 1.5% 2% 3% 4.5% 7.7% 
100% 0.8% 1.7% 2.2% 3.4% 5.2% 8.8% 
% contacts treated                                          Proportion of incident cases among contacts 
 
 4.5% 10% 13% 20% 30% 50% 
25% 0.1% 0.2% 0.3% 0.4% 0.6% 1% 
50% 0.2% 0.4% 0.5% 0.8% 1.2% 2% 
75% 0.25% 0.5% 0.7% 1.1% 1.6% 2.8% 
100% 0.3% 0.7% 0.9% 1.4% 2% 3.5% 
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initiation rate did not seem to affect the results. The influence of changing the TB transmission rate and 
reactivation rate did not seem remarkable.  
The percentages in the table below are obtained by subtracting the incidence in 2030 from the incidence 
in 2020 and scaling it by dividing it by incidence in 2020 and expressing it as a percentage. 
                                 Table 4: Reactivation rate of TB 

























% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.7% 0.2% 
50% 1% 0.3% 
75% 1.3% 0.5% 
100% 1.5% 0.6% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 1% 0.3% 
50% 1.5% 0.5% 
75% 1.9% 0.7% 
`100% 2.2% 0.9% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.8% 0.2% 
50% 1.3% 0.4% 
75% 1.6% 0.6% 




                      Table 5: HIV incidence rate 
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% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.9% 0.2% 
50% 1.4% 0.4% 
75% 1.8% 0.6% 
`100% 2% 0.8% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 1% 0.3% 
50% 1.5% 0.5% 
75% 1.9% 0.7% 
`100% 2.2% 0.9% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 1% 0.2% 
50% 1.5% 0.5% 
75% 1.8% 0.7% 




                 Table 6:  Sensitivity analysis changing the TB transmission rate. 










        TB transmission in 2030 projected at a rate half as that 2020 and the extrapolated value 


















% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.8% 0.2% 
50% 1.2% 0.4% 
75% 1.6% 0.6% 
`100% 1.7% 0.8% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 1% 0.3% 
50% 1.5% 0.5% 
75% 1.9% 0.7% 
`100% 2.2% 0.9% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.9% 0.3% 
50% 1.4% 0.5% 
75% 1.7% 0.6% 
`100% 2% 0.8% 
23 
 
                                    Table 7: ART initiation rate changed 















We then ran a sensitivity analysis by changing the following parameters by 25%: a) treatment coverage 
and treatment success proportion of TB in SA, b) latent protection factor (LPF), c) case fatality ratio of 
TB and d) proportion of patients who were on anti-tuberculous therapy in South Africa. Of these, we 
found that the latent protection factor (tables 8A and 8B) and the treatment coverage rate (tables 11A 
and 11B) in South Africa were the ones which affected the results the most, while the other two did not 
change the impact of interventions on incidence by a huge margin. Reduction in the latent protection 
factor did not impact the reduction in incidence due to our intervention. However, increasing the LPF 
(i.e proportion of latent TB patients who are re-infected) led to an increase in the impact of the 
intervention which in turn was proportion to the coverage of ACF (i.e in a setting with higher risk of 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.9% 0.3% 
50% 1.5% 0.5% 
75% 1.8% 0.7% 
`100% 2.1% 0.9% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 1% 0.3% 
50% 1.5% 0.5% 
75% 1.9% 0.7% 
`100% 2.2% 0.9% 
% contacts treated Effective infectious 
duration 3 months 
6 months 
25% 0.9% 0.3% 
50% 1.5% 0.5% 
75% 1.8% 0.7% 
`100% 2.1% 0.9% 
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reinfection with TB if a higher ACF coverage is achieved , then the intervention can give some impact). 
Again, this was noticed only in the group which was treated earlier and for those with an average 
duration of infection of 6 months, there was no impact of intervention between baseline model and 
increasing the LPF.  
Decreasing the current TB coverage of the national program in SA increased the impact of ACF tracing. 
Increasing the current TB coverage to 95% decreased the impact of our intervention in the 3-month 
infectious duration group. ACF tracing had a lesser impact than the national TB program when the 
coverage was set at 95% and the average duration of infection was 6 months. That is because with a 
95% coverage proportion of TB patients, the patients started on therapy under the national program 
earlier than the 6-month period, making this intervention superfluous at that time point. In fact, if ACF 
was conducted such that the patient was infectious on an average for 6 months then it would perform 
poorly as compared to the national program with a coverage of 95%. 
The percentages in the table below are obtained by subtracting the incidence in 2030 from the incidence 











The results were as follows: 
Table 8A: Latent protection factor (baseline model value was 0.28) 
Reducing it by 25% (setting it at 0.21) 
% contacts covered Average infectious duration=3 
months 
Average infectious duration=6 
months 
0.25 0.9% 0.2% 
0.5 1.4% 0.4% 
0.75 1.7% 0.6% 
1 2% 0.8% 
 
Table 8 B: Increasing LPF by 25% (setting it at 0.35) 
% contacts covered Average infectious duration 3 
months 
Average infectious duration 6 
months 
0.25 1.1% 0.3% 
0.5 1.8% 0.6% 
0.75 2.2% 0.8% 












Table 9 A: Treatment success proportion (baseline model among HIV negative - 0.82 and HIV 
positive – 0.72 
Reducing the treatment success proportion by 25% in HIV positive and negative groups 
% contacts covered Average infectious duration 3 
months 
Average infectious duration 6 
months 
0.25 1% 0.3% 
0.5 1.6% 0.5% 
0.75 2% 0.7% 
1 2.3% 0.9% 
 
Table 9B: Increasing the treatment success proportion by 25% in HIV positive and negative 
groups.  
% contacts covered Average infectious duration 3 
months 
Average infectious duration 6 
months 
0.25 1% 0.3% 
0.5 1.6% 0.5% 
0.75 1.9% 0.7% 








     Table 10A: Changing the case fatality ratio for TB (baseline model value was 0.15) 
Reducing the case fatality ratio by 25% (0.11) 
% contacts 
covered 
Average infectious duration 3 
months 
Average infectious duration 6 
months 
0.25 1% 0.3% 
0.5 1.6% 0.5% 
0.75 2% 0.8% 
1 2.3% 1% 
          
 
 
           Table 10B: Increasing the case fatality ratio by 25% (0.18) 
% contacts covered Average infectious duration 3 
months 
Average infectious duration 6 
months 
0.25 1% 0.3% 
0.5 1.6% 0.6% 
0.75 1.9% 0.8% 












Table 11A: Change in TB treatment coverage (baseline 76%)  
Reducing the TB treatment coverage by 25% (57%)  
% contacts covered Average infectious duration 3 months Average infectious duration 6 months 
0.25 1.7% 0.8% 
0.5 2.4% 1.4% 
0.75 2.8% 1.7% 
1 3% 2% 
 
Table 11B:  the TB treatment coverage by 25% (95%) 
% contacts covered Average infectious duration 3 
months 
Average infectious duration 6 months 
0.25 0.2% -0.3% 
0.5 0.4% -0.6% 
0.75 0.6% -1% 
1 0.8% -1.5% 
The negative values in Table 11B indicate that if 95% coverage with antituberculosis coverage is 
implemented in the national program, then the national program will reduce the incidence more than 







4. DISCUSSION:  
We used a calibrated population- based model to project the effect of tracing household contacts patients 
with active tuberculosis in South Africa. Our results suggest that contact tracing in South Africa would 
help reduce the incidence of tuberculosis to some extent depending on how quickly the contacts are 
traced and what proportion of incidence TB cases is found in contacts. The impact of household contact 
investigation depended on the proportion of incident cases occurring among contacts, the average 
amount of infectious person-time per patients, and the coverage of the intervention among eligible 
contacts. This suggests that contact tracing is most effective when the proportion of incident cases 
among contacts is high and when a high proportion of them are treated early. It is worth noting that 
assuming a contact is detected at 3-months of being infectious duration of a contact, a 25% treatment 
coverage of contacts where 10% of incident cases are among contacts offers more reduction in incidence 
as a 100% treatment coverage with 4.5% contacts with incident TB. This suggests that in a high burden 
setting where the possibility of TB among contacts is higher, there is a benefit to reduction of the 
incidence using ACF. 
We tested our interventions across various percentages of tuberculosis that could be attributed to 
contacts of TB patients. We tested the interventions where we set the percentage of TB in contacts was 
at 4%, 10%, 13%, 20% and 30%. Values for TB in contacts of patients has found to range from 1% to 
4.5%. (15,16,40,41). So, we think that our simulations which are for the 4% section of active contacts 
with TB may mimic the ground realities in South Africa more accurately. However, this is a percentage 
for the entire nation. It is possible in certain areas this proportion may go higher. This implies that the 
best way that contact tracing may be effective is through early tracing and a higher coverage of 
treatment among contacts. As noted in Tables 2A to 2C, the reduction of incidence is highest (8.8%) 
when all the contacts with incident TB are traced within 3 months of becoming infectious. Complete 
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coverage of all incident cases who are contacts may not be very possible in real life. In that case, timing 
of tracing becomes crucial. As our simulation shows the earlier the contacts are traced the bigger the 
drop in incidence. There may even be a rationale for preventive therapy to contacts so that they can be 
prevented from being infected and therefore infectious (42). 
We also noted that the duration of infectiousness averted in contacts also has an impact on the incidence 
trends. As seen in table 1, irrespective of proportion of incidence of TB among contacts and the 
proportion covered with anti-tuberculous therapy, allowing an increase in delay of detection by even 3 
months leads to the effectiveness of the intervention halving. So, our model suggests that along with a 
higher proportion of incident cases among contacts, the timing of detection also matters, which informs 
that a delay of even 3 months can reduce the effectiveness of treatment. This therefore underscores the 
importance of active case finding through contact tracing in high burden countries. It also emphasizes 
early detection of TB cases to reduce their average infectious time. This could mean earlier diagnosis of 
the index case- which can in turn be done by improving access to healthcare. 
The WHO has released their screening guidelines which gives certain principles of screening for TB, 
namely: a) good infrastructure should be in place before screening is initiated; b) high risk groups should 
be targeted for screening instead of indeterminate mass screening; c) algorithms should be chosen based 
on accuracy and feasibility; d) screening should be ethical; and e) screening for TB should be combined 
with other public health delivery systems with f) periodic assessments of screening system (18). The 
same document strongly recommends screening in household or close contacts and subpopulations with 
high levels of undetected TB (1% or higher) as well as in subpopulations with poor access to healthcare 
(18).  Our findings are consistent with the WHO guidelines on contact tracing, in that they show greater 
effectiveness when implemented in a setting where contacts form a higher burden of the TB incident 
cases and that early detection can help reduce the infective duration.  
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Studies in Vietnam by Fox et al and the ZAMSTAR trial have showed that case detection rates increased 
after contact tracing of index TB cases was implemented (14,15) The relative risk was 2.5 for 
cumulative incidence of tuberculosis in the contact tracing arm as compared to the control arm in the 
study by Fox et al (14).  These studies also imply a higher case burden among contacts which is detected 
late. Hanrahan et al were unable to show an increased case detection among contacts which ended up 
showing no difference in incidence rates among the contact tracing and passive case finding arm (16). 
The authors state that they used Xpert RIF to diagnose TB as opposed to cultures and assume that could 
have led to a lower detection rate (16). We have not specified any diagnostic method in our simulation. 
We have assumed that whatever contacts have TB would be diagnosed with a 100% accuracy and 
treated with a success rate that is proportional to the current rates in South Africa. This may not be a 
very realistic assumption, and we think that to achieve the 25% rate of covering contacts with TB, a 
higher proportion may need to be tested to achieve those targets considering the possibility of false 
negatives.  
As Golub et al have noted, ACF is should be based on 1) prevalence of the disease, 2) epidemiological 
importance, 3) chances of being detected otherwise and 4) cost. South Africa has a high disease burden 
of TB where contact tracing needs to be implemented to reduce the incidence. As per our model, the 
epidemiological importance of the ACF is demonstrated by the delay in detection reducing the 
effectiveness of interventions. Since the anti-tuberculous therapy coverage in South Africa was 76% in 
2018 it is evident that early case detection is still an issue (20). Our model also gives a good basis for 
implementation of ACF based on the criteria provided by Golub et al.  
Based on our model we would recommend that contact tracing in areas of high disease burden in South 
Africa would be a way to start active case finding in South Africa. As noted, incidence reduction is very 
sensitive to two factors i.e.: proportion of contacts with incident TB and the averted period of 
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infectiousness. This implies that time is an important component in ACF. So, it is critical that the 
duration of time when undiagnosed contacts can be infectious should be reduced to the largest extent 
possible. This may involve incentives or home-based tracking especially in high burden areas or 
provinces. The intervention can be implemented in phases.  
Our model is consistent with the current status of the TB-HIV epidemic in South Africa and the future 
trends in it. However, the burden of TB is not the same across South Africa and it may differ among 
communities (43). Our model may not be able to capture these differences, even though it does seem to 
reflect the overall trend in South Africa. There may be areas in South Africa where contact tracing may 
give a more significant decrease in TB incidence as compared to other areas not densely populated or 
with a higher socio-economic status.  
 We did not assess reinfection in previously treated individuals. Reinfections form a significant burden 
of TB in South Africa as per Marx et al who showed in a retrospective cohort study that 51% of cases in 
SA were due to reinfections (44). Drug resistance rates in both HIV and TB may change the prevalence, 
mortality and the rates of movement from one compartment to another (e.g., successful treatment), and 
we have not modeled these parameters. The TB and HIV epidemics are fairly correlated in South Africa, 
and a change in HIV incidence or prevalence can affect the tuberculosis levels.  
We also had a very simplified model of contact tracing where the rate of diagnosis was reflected purely 
by the average duration of infectiousness. We could have modeled a distribution of individual diagnosis 
rates and a separate duration of infectiousness. We have also constructed the model such that all contacts 
who are tested for TB and are positive are also started on anti-tuberculous therapy. This may not always 
be the case. We also assumed that all patients who were HIV positive and found to have TB were started 
on ART as well within the same year. This, while true on a policy level may not be true in real life. Our 
incidence rate of MTCT infections of HIV may also be on the higher side considering that we are basing 
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it on current incidence estimates and that as the population on ART grows, this number may reduce over 
time.  
5.CONCLUSION 
Our model shows that contact tracing may help in reducing the incidence of TB in South Africa if 
contacts are traced early in their illness and close contacts account for a substantial proportion of all 
incident TB. This model is most susceptible to changes in the proportion of patients under coverage for 
anti TB therapy where if the proportion increases, it becomes more effective than the intervention and a 
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